

Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11

Laura C. Coates, Oliver FitzGerald, Philip J. Mease, Dafna D. Gladman, Vibeke Strand, Niti Goel, Ina Campbell, Gerald Krueger, Neil J. McHugh, and Philip S. Helliwell

ABSTRACT. This module reflected work within the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) to develop and validate composite disease activity measures in psoriatic arthritis (PsA). At the Outcome Measures in Rheumatology (OMERACT) 8 Meeting, a core set of domains to be assessed in randomized controlled trials (RCT) and longitudinal observational studies of PsA was agreed upon. At OMERACT 10, 5 proposed composite responder definitions for PsA were reviewed and discussed, including new data from the GRACE (GRAppa Composite Exercise) study. At OMERACT 11, ongoing retrospective analyses of RCT data using the 3 proposed measures (Composite Psoriatic Disease Activity Index, Psoriatic Arthritis Disease Activity Score, and Arithmetic Mean of the Desirability Function) were discussed in detail. There was agreement that developing composite outcome measures for use in RCT and longitudinal observational studies in PsA was important. Concerns were expressed regarding development of a single measure that encompassed diverse domains, such as joint counts, quality of life (QOL), and disability measures. It was emphasized that the use of any composite measure should include the ability to differentiate between activity in individual domains, such as enthesitis or psoriasis, such that the effect of each could be assessed independently. It was also agreed that patients would be systematically involved in further development and refinement of composite measures. Future plans include qualitative work with patients to explore their experience of disease activity and statistical modeling to explore how each of the proposed measures will perform in different disease subgroups. (First Release Feb 1 2014; J Rheumatol 2014;41:782–91; doi:10.3899/jrheum.131250)

Key Indexing Terms:

PSORIATIC ARTHRITIS
ASSESSMENT

CLINICAL OUTCOME MEASURES
DISEASE ACTIVITY

Psoriatic arthritis (PsA) is a multifaceted disease with involvement of peripheral joints, skin, nails, entheses, soft tissues of the digits (i.e., dactylitis), and axial skeleton. Outcomes research in PsA has generally lagged behind that in rheumatoid arthritis (RA). The lack of validated outcome measures comprising all domains of disease involvement in PsA remains a particular challenge. Many different outcome

measures for each of the separate aspects of the disease are available, but most are borrowed from related diseases such as RA, axial spondyloarthritis (axSpA), or psoriasis, and only some have been validated in PsA. Until recently there were no composite outcome measures for PsA that included all of the mentioned aspects of disease involvement.

Composite measures used in RA to assess disease

From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK.

L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology

Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACP, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPATH, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds.

Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk

severity and in responder indices such as the Disease Activity Score (DAS) with the related European League Against Rheumatism (EULAR) Response Criteria, or the American College of Rheumatology (ACR) Response Criteria, primarily focus on the assessment of peripheral joint activity. The DAS includes an acute-phase response marker, and the ACR Response Criteria include acute-phase response, pain, and physical function, in addition to specific measures of peripheral arthritis; however, these do not fully represent all aspects of PsA. While used in many randomized controlled trials (RCT) to assess peripheral joint disease activity, and indirectly through the patient global assessment to assess other aspects of PsA, these composite measures omit direct evaluation of the additional domains of PsA such as enthesitis, dactylitis, and axial and skin disease.

Recognition of this dearth of validated outcome measures in PsA led to the formation of a joint Outcome Measures in Rheumatology (OMERACT)/Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) working group to develop a research agenda of outcome measurement in RCT in PsA. There are currently more than 400 members of GRAPPA internationally, including rheumatologists, dermatologists, radiologists, epidemiologists, and industry and patient service league representatives.

The first step was to hold an outcome measures workshop in PsA at OMERACT 7 (Asilomar, California, USA, 2004). Discussion of potential domains for inclusion in RCT in PsA led to a research agenda to identify optimal measures for each aspect of psoriatic disease and to develop effective instruments where none existed¹. Significant further progress was made at the OMERACT 8 conference (Malta, 2006). There, consensus was reached on the core domain set for PsA trials², based on a series of projects conducted following OMERACT 7 including a clinician Delphi exercise and data mining from completed RCT. At OMERACT 8, no data were available on composite measures designed to assess multiple domains of PsA.

Since OMERACT 8, GRAPPA has been actively working to develop reliable diagnostic and assessment tools for PsA, including clinical, laboratory, imaging, tissue analysis, and composite measures of disease activity. This work is pursued both in individual clinical research centers as well as collaboratively among members of the group. At the GRAPPA Annual Meeting in 2008 (Leeds, UK), work on different proposed composite indices was presented, including many of the measures discussed below. Different potential approaches were also discussed, e.g., the development of the DAS in RA and the Ankylosing Spondylitis Disease Activity Score (ASDAS) as well as the British Isles Lupus Assessment Group score in systemic lupus erythematosus (SLE)³. Breakout groups discussed these different options, and a large collaborative exercise [GRAPPA Composite Exercise (GRACE)] was proposed to initiate the

development and validation of a GRAPPA/OMERACT composite disease activity measure for PsA⁴. This work led to a special interest group at OMERACT 10 being convened in 2010. At the OMERACT 11 session, results of ongoing work with the GRACE dataset and analysis of some proposed composite measures were presented.

Aims of the Module

Philip Mease briefly reviewed work and introduced the aims of the module at OMERACT 11: (1) to present a literature review of various outcome measures that individually reflect different domains of PsA, and compare them with other composite measures of disease activity in RA; (2) to highlight the patient's perspective with an illustration of the many ways in which this disease can affect a single patient over time; (3) to present work to date assessing performance of the proposed PsA responder indices in datasets from completed RCT and independent populations; (4) to provide a forum for discussion of these proposals and an opportunity for feedback and debate; and (5) to define issues that remain in the research agenda regarding domains and instruments for their assessment in PsA.

Review of Outcome Measures Used in PsA Clinical Trials

A number of outcome measures have been developed and used in PsA to measure different aspects of the disease^{2,5,6,7,8,9,10} (Table 1). For arthritis, the majority of measures used in RCT in PsA were adopted from RA. Dr. Laura Coates summarized data regarding the use of ACR and DAS outcomes in PsA, explaining that these measures had been shown to be responsive in polyarticular PsA in clinical trial datasets¹¹. Deficiencies included that 28-joint counts are not reliable in PsA, particularly in oligoarthritis¹². The Psoriatic Arthritis Response Criteria (PsARC) was the first composite measure designed specifically for PsA and uses a composite measure of tender joint counts (TJC) and swollen joint counts (SJC) with patient and physician global assessments of disease activity¹³. However, it was arbitrarily derived and does not specifically incorporate other features of PsA such as enthesitis, dactylitis, or axial or skin disease. The use of the physician and patient global visual analog scale (VAS) scores may partially reflect activity in these elements of disease depending on the wording of the VAS questions.

A brief summary of new articular composite measures specifically designed for PsA was presented, i.e., the PsA Joint Activity Index (PsAJAI) and the Disease Activity in Psoriatic Arthritis (DAPSA). Both scores have specifically excluded skin disease activity, although for different reasons. The PsAJAI, a response measure using a 30% reduction in disease activity as the cutoff, was developed from and tested in 2 independent samples from RCT datasets of tumor necrosis factor (TNF) inhibitors using

Table 1. Summary of current composite measures.

	DAS28	PsAJAI	DAPSA	CPDAI	PASDAS	AMDF
Arthritis (joint counts)	28	66/68	66/68	66/68	66/68	66/68
Skin disease	N	N	N	Y	N	N
Enthesitis	N	N	N	Y	Y	N
Dactylitis	N	N	N	Y	Y	N
Spinal disease	N	N	N	Y	N	N
Health-related quality of life	N	N	N	Y	Y	Y
Physical function	N	Y	N	Y	N	Y
Patient's arthritis disease activity assessment	N	N	N	N	N	Y
Patient's skin disease activity assessment	N	N	N	N	N	Y
Patient's global disease activity assessment	Y	Y	Y	N	Y	Y
Patient's pain assessment	N	Y	Y	N	N	N
Physician's global disease activity assessment	N	Y	N	N	Y	N
Acute-phase response	Y	Y	Y	N	Y	N

DAS28: Disease Activity Score 28 joints; PsAJAI: Psoriatic Arthritis Joint Activity Index; DAPSA: Disease Activity in Psoriatic Arthritis; CPDAI: Composite Psoriatic Disease Activity Index; PASDAS: Psoriatic Arthritis Disease Activity Score; AMDF: arithmetic mean of desirability functions.

statistical modeling. Therefore, it has been validated in a predominantly polyarticular, not oligoarticular, subset of disease. It ultimately excluded a measure of skin disease activity because the magnitude of skin disease improvement in these trials was so large that it overwhelmed responses in articular disease¹⁴. The DAPSA score¹⁵ was suggested for PsA after principal component analysis of data in 105 patients with PsA found that the key disease domains were represented by measures included in the DAREA (Disease Activity index for Reactive Arthritis), originally developed for reactive arthritis¹⁶. In this analysis, skin disease activity was proposed as a component, but did not quite reach significance, possibly because of the low level of skin disease in this specific patient cohort. Components of the DAREA include SJC and TJC, patient global score, pain score, and C-reactive protein (CRP). Ultimately, both the PsAJAI and the DAPSA have included only specific measures of articular disease; although the global patient reported scores for disease activity and pain may partially encompass other elements of PsA, it is unclear to what extent.

For psoriasis, several skin measures have been developed for use in RCT and longitudinal observational studies. Interestingly, patients enrolled in PsA clinical trials often have low body surface area (BSA) involvement of psoriasis and thus may not be reliably evaluated with the Psoriasis Area and Severity Index (PASI) score¹⁷. The PASI exhibits poorer performance in subjects with < 3% BSA involvement. A "target lesion" score may be used, where 1 lesion is evaluated over the course of the study⁵, but this does not reflect the total extent of disease involvement nor which areas are involved. Newer scoring methods such as the Lattice System Physician's Global Assessment of psoriasis¹⁸ and the Copenhagen Psoriasis Severity Index¹⁹ were also briefly discussed. Nail involvement is also a common problem in psoriasis, and particularly in PsA. The Psoriasis Nail Severity Score, developed in Bath²⁰, has been

used in studies; and even more recently, several PsA trials have successfully incorporated a modified Nail Psoriasis Severity Index (mNAPSI) score for evaluation of responses in nail involvement²¹.

Recognizing the importance of enthesitis and dactylitis as domains, measures for these clinical features have evolved over the past several years and are now routinely performed. Several measures of enthesitis, which assess different groups of enthesal insertion sites, are being used, and it is anticipated that as these are evaluated, a single measure may emerge as standard for PsA. Measures specifically developed for PsA, such as the Leeds Enthesitis Index, and measures developed in a mixed group of patients with spondyloarthritis (SpA), such as the SPARCC (Spondyloarthritis Research Consortium of Canada) enthesitis index, are now being used in ongoing research. It was highlighted that up to half of patients with PsA experience dactylitis at some point in their disease course. Measurement of this phenomenon has been evaluated by Helliwell, *et al* who have compared existing measures such as digit counts and semiquantitative scoring of dactylitis and have developed the dactylometer, which allows quantification of clinical digit swelling^{22,23}.

Spinal involvement in PsA has generally been under-researched, with no specific clinical trials in this group of patients. Spinal involvement is not commonly measured in RCT in PsA, partly because of difficulties assessing this disease component. Physical examination measures of the spine are reliable in axial PsA²⁴ and reflect not only disease activity but also significant cumulative damage. Measures of axial disease activity used in axSpa, including the Bath Ankylosing Spondylitis Disease Activity Index and ASDAS, have been shown to correlate with constructs of disease activity in axial PsA^{25,26,27}, but not to differentiate between peripheral and axial disease activity, casting doubt on their construct validity in PsA.

A Patient's Perspective

Next, a patient representative provided valuable perspective as an individual with PsA, but also as a physician who treats PsA and conducts research in PsA. Her initial symptoms were primarily axial and enthesal, and although she visited a rheumatologist early in her disease course, she came away without a diagnosis because no significant arthritis or skin disease was present at onset, and initial laboratory assessments and radiographs were negative. Cognizant of US healthcare system issues around preexisting conditions, she did not return for diagnosis or treatment when synovitis developed about 1 to 2 months later. Instead, she reported she chose to self-manage the disease with minocycline and ibuprofen. She originally thought she had AS, but once she developed onycholysis of her large toenails, she recognized she most likely had PsA. She shared that the axial symptoms and fatigue had been some of her worst symptoms and that she also changed jobs to minimize the effect of stress, travel, and lack of sleep on her health. She recognized in herself complaints that her patients had made to her about, e.g., walking on marbles related to metatarsal pain, hobbling to the bathroom in the morning because of stiffness, keeping nail polish on her toenails to avoid showing evidence of her onycholysis. Eventually she returned to her rheumatologist, who recognized her reluctance to start a TNF inhibitor and instead prescribed sulfasalazine (SSZ). She was thrilled as was her rheumatologist when she reported how well SSZ had worked for her symptoms, especially the stiffness and peripheral joint disease. She mentioned that stress and lack of sleep continued to precipitate flares, and she has made it a priority to manage these. She recognized that SSZ has probably been a temporizing measure because it has not worked as well for her axial symptoms or nail disease as it has for her peripheral disease. Her disease and its effect on her and her family life were evolving, and her therapy would also evolve. Ultimately, she stressed that as a researcher and physician as well as a patient, the currently available tools did not accurately assess the effect of PsA on her disease or her life.

Current Proposed Composite Outcome Measures — CPDAI

Work developing 2 key composite measures has been initiated and led by members of GRAPPA. FitzGerald and colleagues developed a composite outcome measure based on the GRAPPA treatment grid published by Ritchlin, *et al*²⁸. For the Composite Psoriatic Disease Activity Index (CPDAI), a score of 0–3 is assigned to each of the 5 domains (arthritis, enthesitis, dactylitis, skin and spinal disease) of PsA based on disease activity and effect of disease for this domain (Table 2). The scores are added together to give a total score of 0–15, thus providing an overall assessment of disease activity²⁹. One concern raised during the development of this measure was that patients

with severe disease activity in only 1 domain may be disadvantaged by a relatively low total score. Two potential solutions have been proposed: first, modified classification, where anyone with a single domain scored as severe would be classified as “severe” overall; second a “modified CPDAI,” where the total score is divided by the number of active domains involved yielding a mean score.

Oliver FitzGerald presented validation data for CPDAI from analysis of the PRESTA (Psoriasis Randomized Etanercept Study) data³⁰. Individual measures of joint disease, enthesitis, and dactylitis showed similar changes between higher and lower doses of etanercept, but a superior response was evident with the higher dose for skin disease. There were a few limitations of this dataset. Like many RCT of PsA, the majority of patients had polyarticular disease despite its not being an inclusion criterion, so this dataset does not provide evidence for responsiveness of these measures in oligoarthritis. Like many RCT in PsA, there was no specific assessment or measure of axial disease in this trial. For this reason, a modified CPDAI assessing 4 domains (peripheral joint disease, skin, dactylitis, and enthesitis) was scored from 0–12 rather than 0–15.

The CPDAI showed good responsiveness to change and identified a significant difference between treatment groups at 12 weeks that was likely driven by the differential response in skin disease ($p = 0.049$). In stepwise regression analysis, enthesitis, the Health Assessment Questionnaire (HAQ), dactylitis and the Dermatology Life Quality Index all contributed significantly to the CPDAI values at baseline³¹. In comparison, the DAPSA score showed a significant improvement between baseline and 12 weeks in both treatment groups but did not identify a significant difference between the treatment groups at Week 12. Thus, while both the DAPSA and CPDAI show responsiveness in measures of arthritis, the CPDAI has a potential advantage in that it can also reflect changes in the other domains of PsA.

GRAPPA COMPOSITE EXERCISE

Following the GRAPPA annual meeting in 2008 and as part of the preparation for OMERACT 10, GRAPPA initiated GRACE, which aimed to develop an inclusive composite outcome measure based on real patient data. Longitudinal observational data were collected on a large cohort of patients with PsA internationally. Individual outcomes were collected as well as patient-reported outcome measures that assessed disease activity in all of the domains of PsA. Where no consensus had been reached regarding optimal outcome measures for each component of disease, e.g., enthesitis, multiple measures were collected to allow comparison of different indices. Patients were classified by their treating physician into 2 groups: those with active disease requiring a treatment change and those, in the opinion of their treating physician, with low disease activity

Table 2. Example Case 1. Scores of components of psoriatic arthritis disease activity and response measures.

Element	Score	CPDAI Score	PASDAS Score	AMDF Score
TJC	0	0	0	1
SJC	0		0	1
HAQ	0.4		—	0.84
LEI	5	2	0.41	—
Dactylitis	0	0	0	—
PASI	8		—	—
DLQI	13	2	—	—
BASDAI	5.6		—	—
ASQoL	14	3	—	—
PsAQoL	9	—	—	0.52
SF-36 PCS	30	—	1.39	0.27
VAS patient global activity	65	—	1.28	0.28
VAS patient skin disease activity	10	—	—	0.8
VAS patient joint disease activity	35	—	—	0.58
VAS physician global activity	60	—	1.39	—
CRP	25	—	0.33	—

CPDAI: Composite Psoriatic Disease Activity Index; PASDAS: Psoriatic Arthritis Disease Activity Score; AMDF: arithmetic mean of desirability functions; TJC: tender joint count; SJC: swollen joint count; HAQ: Health Assessment Questionnaire; LEI: Leeds Enthesitis Index; PASI: Psoriasis Area and Severity Index; DLQI: Dermatology Life Quality Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASQoL: Ankylosing Spondylitis Quality of Life; PsAQoL: Psoriatic Arthritis Quality of Life; SF-36 PCS: Medical Outcome Study Short Form-36 Survey physical component score; VAS: visual analog scale; CRP: C-reactive protein.

or in remission. The 2 groups were then compared to see where significant differences existed between them and which individual outcome measures accounted for this difference.

Recruitment to GRACE has been completed, with baseline data collected on 503 patients with PsA and followup data available. Analysis of the many outcome measures included in the dataset has shown a difference in all key variables encompassing arthritis, skin disease, enthesitis, dactylitis, axial disease, functional ability, and QOL for those undergoing treatment change and those not; except for the mNAPSI, Maastricht Ankylosing Spondylitis Enthesitis Score, erythrocyte sedimentation rate, and Bath Ankylosing Spondylitis Metrology Index.

Current Proposed Composite Outcome Measures — Psoriatic Arthritis Disease Activity Score

The first methodology pursued by the OMERACT PsA group was to develop a weighted composite disease activity score called the Psoriatic Arthritis Disease Activity Score (PASDAS) with methodology used to develop the DAS and ASDAS. A principal component analysis was performed for all variables included in disease activity measures, with transformation for all variables to improve variable distribution. Factor analysis identified 5 components: (1) patient and physician VAS scores of disease activity, (2) skin activity, (3) TJC and enthesitis, (4) SJC and dactylitis, and (5) CRP. However, with regression analysis, nearly 80% of variability (adjusted R²) was provided by the patient global

disease VAS, and over 90% by just 3 VAS scores (patient global assessment, patient assessment of skin disease, and physician global assessment)³². At OMERACT 10 and at a later GRAPPA meeting adjacent to EULAR 2010, Philip Helliwell therefore proposed the PASDAS as a composite of 3 VAS scores. Significant concern was voiced about using only 3 subjective VAS scores to measure disease activity, particularly by GRAPPA attendees from sponsors who felt that such a disease activity measure would not be supported by regulatory authorities as a robust tool.

Following this discussion, a revised PASDAS was developed. Principal component analysis revealed 7 components that approximated to the following domains: patient-reported measures [excluding the mental component summary score (MCS) of the Medical Outcomes Study Short Form-36 survey (SF-36)], skin, peripheral joint counts, dactylitis, enthesitis, acute-phase response, and the SF-36 (MCS). In the subsequent forward stepwise regression (FSR), 2 of the variables (patient and physician global VAS scores) accounted for about 90% of the total variance in scores (as seen in the previous incarnation of the PASDAS). A hierarchical multiple regression analysis then considered these variables where both global VAS scores were entered in step 1; dactylitis, enthesitis, CRP, SJC, and SF-36 PCS (physical component summary score of the SF-36) in step 2; and TJC and SF-36 MCS (neither of which were significant in the FSR) in step 3. The SF-36 MCS did not contribute to the model variance and was therefore omitted from the final PASDAS³³.

The final PASDAS is represented by the following equation:

$$\text{PASDAS} = (((0.18 \times \sqrt{\text{physician global VAS}}) + (0.159 \times \sqrt{\text{patient global VAS}}) - (0.253 \times \sqrt{\text{SF36} - \text{PCS}}) + (0.101 \times \text{LN}(\text{swollen joint count} + 1)) + (0.048 \times \text{LN}(\text{tender joint count} + 1)) + (0.23 \times \text{LN}(\text{Leeds Enthesitis Index} + 1)) + (0.377 \text{LN}(\text{tender dactylitis count} + 1)) + (0.102 \times \text{LN}(\text{CRP mg/dl} + 1)) + 2) * 1.5.$$

Current Proposed Composite Outcome Measures — Arithmetic Mean of Desirability Functions

The second approach was that suggested by Fransen, *et al*³⁴, where desirability functions were developed for variables deemed important in assessing disease activity, based on core domains selected for PsA RCT at OMERACT 8². The desirability function can be used to combine multiple responses into 1 measure by translating each variable onto the same scale from 0 (a completely unacceptable or undesirable level) to 1 (a completely desirable or ideal response value). Then these transformed variables can be averaged to give a total score. Desirability functions for TJC and SJC, HAQ, and the patient global assessment of disease activity VAS were derived using expert consensus data gathered by an Internet-based survey of GRAPPA members during development of the minimal disease activity score³⁵. Remaining functions [patient VAS for skin, patient VAS for joints, PASI, and Psoriatic Arthritis Quality of Life index (PsAQoL)] were developed with expert consensus data obtained from 109 responses in a subsequent Internet survey (85 rheumatologists and 24 dermatologists). Cutoffs were determined according to the median of responses (Table 2), and used to transform each variable into linear functions ranging from 0 (totally unacceptable state) to 1 (normal). The 8 transformed variables were then combined using the arithmetic mean [arithmetic mean of desirability functions (AMDF)].

Performance of the PASDAS and AMDF in RCT and Observational Cohort Datasets

The OMERACT PsA group aimed to work with many different organizations to apply and test these proposed composite measures in existing RCT and observational cohort datasets prior to the OMERACT 11 module. Unfortunately, many existing datasets do not include all the variables required to calculate the proposed composite measures. There were also delays in obtaining RCT data for this purpose: only PRESTA data as discussed above were available. A few unavailable variables, e.g., SF-36, PsAQoL, and axial disease measures resulted in minor modifications to calculations of the CPDAI, PASDAS, and AMDF composite measures.

All the composite measures (DAPSA, CPDAI, PASDAS, and AMDF) were compared using analysis of covariance to compare effect sizes, and DAS28 was included as a control measure. The largest effect size was seen with the AMDF

score (> 2) with a significant difference between effect sizes in the 2 treatment regimens at 12 weeks. Effect sizes for the CPDAI and PASDAS were also high (~1.5) with lower effect sizes seen with DAPSA and DAS28.

Case Examples

Case 1. A 34-year-old man presented to rheumatology with a 6-year history of inflammatory back pain. He had had skin psoriasis since childhood and also had active enthesitis affecting 1 Achilles tendon and both medial femoral condyles and lateral elbow epicondyles. He had no peripheral arthritis or dactylitis. He had been treated by his physician with physiotherapy and oral nonsteroidal anti-inflammatory drugs with no relief of symptoms.

Table 2 gives the components of the composite scores to illustrate how they are calculated. Using the CPDAI, Case 2 scored as follows: peripheral arthritis: 0; skin disease: 2; enthesitis: 2; dactylitis: 0; axial disease: 3. His total CPDAI score was 7, indicating severe disease, and he was given a TNF inhibitor because of his severe spinal disease. When applying the PASDAS weighted score in this case, the total score was 6.03, indicating high disease activity under proposed cutoffs. Using the AMDF score, the total score was 0.53 (scale 0 to 1, 1 is no disease activity), indicating moderate disease activity according to cutoffs defined by Fransen, *et al*. The elements of all these scores are shown in Table 2. Interestingly, the absence of activity in 1 element of disease (peripheral arthritis) in this case causes a “perfect” score of 1 to be attributed to both TJC and SJC in the AMDF, which inflates the score, reducing disease activity from high to moderate using this scoring method.

Case 2. A 34-year-old woman developed psoriasis at the age of 16 years and was then diagnosed with PsA at age 22. At the time of assessment, she was reviewed in a combined clinic and was to begin using a TNF inhibitor. She had active peripheral polyarthritis with dactylitis in 4 toes. She also had axial disease and active skin psoriasis with scattered plaques all over her body. Using the CPDAI, she scored a total of 10, indicating severe disease: peripheral arthritis: 3; skin disease: 2; enthesitis: 0; dactylitis: 3; axial disease: 2. When applying the PASDAS weighted score, the total score was 6.78, indicating high disease activity under proposed cutoffs. Using the AMDF score, the total score was 0.46, which indicates moderate disease activity³⁴. She was started on adalimumab because of her severe disease affecting both the peripheral and axial skeleton. The elements of all her scores are shown in Table 3. In this case, the absence of significant skin disease and a relatively low HAQ score decreased the AMDF score to moderate rather than high, as it was for the CPDAI and PASDAS, despite high disease activity in the joints.

Case 3. A 37-year-old man had psoriasis since age 4 years and then developed PsA at age 22. He was also being assessed for anti-TNF therapy. He had oligoarthritis affecting the left

Table 3. Example Case 2. Scores of psoriatic arthritis disease activity and response measures.

Element	Score	CPDAI Score	PASDAS Score	AMDF Score
TJC	13		0.13	0.37
SJC	11	3	0.12	0.36
HAQ	0.88		—	0.67
LEI	0	0	0	—
Dactylitis	4	3	0.60	—
PASI	2.3		—	0.82
DLQI	12	2	—	—
BASDAI	2.16		—	—
ASQoL	15	2	—	—
PsAQoL	17	—	—	0.14
SF-36 PCS	30.06	—	1.39	—
VAS patient global activity	65	—	1.28	0.28
VAS patient skin disease activity	10	—	—	0.8
VAS patient joint disease activity	65	—	—	0.28
VAS physician global activity	65	—	1.45	0.28
CRP	24.7	—	0.33	—

CPDAI: Composite Psoriatic Disease Activity Index; PASDAS: Psoriatic Arthritis Disease Activity Score; AMDF: arithmetic mean of desirability functions; TJC: tender joint count; SJC: swollen joint count; HAQ: Health Assessment Questionnaire; LEI: Leeds Enthesitis Index; PASI: Psoriasis Area and Severity Index; DLQI: Dermatology Life Quality Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASQoL: Ankylosing Spondylitis Quality of Life; PsAQoL: Psoriatic Arthritis Quality of Life; SF-36 PCS: Medical Outcome Study Short Form-36 Survey physical component score; VAS: visual analog scale; CRP: C-reactive protein.

first metacarpophalangeal joint and the right metatarsus. He also had 2 enthesitis points and dactylitis of the left fourth toe. Given the different aspects of disease and his ongoing active disease, he was started on disease-modifying antirheumatic drug therapy to control his arthritis and dactylitis. The elements of this man's scores are shown in Table 4. Using the

CPDAI, this man had a total score of 3, indicative of mild disease: peripheral arthritis: 1; skin disease: 0; enthesitis: 1; dactylitis: 1; axial disease: 0. When applying the PASDAS weighted score in this case, the total score was 3.74, indicating moderate disease activity, while the AMDF indicated low disease activity with a score of 0.86.

Table 4. Example Case 3. Scores of psoriatic arthritis disease activity and response measures.

Element	Score	CPDAI Score	PASDAS Score	AMDF Score
TJC	2		0.05	0.8
SJC	2	1	0.11	0.72
HAQ	0.25		—	0.9
LEI	2	1	0.25	—
Dactylitis	2	1	0.41	—
PASI	0	0	—	1
DLQI	0		—	—
BASDAI	0.64		—	—
ASQoL	0	0	—	—
PsAQoL	1	—	—	0.93
SF-36 PCS	46.84	—	1.73	—
VAS patient global activity	15	—	0.62	0.86
VAS patient skin disease activity	0	—	—	1
VAS patient joint disease activity	16	—	—	0.75
VAS physician global activity	7	—	0.48	0.8
CRP	18	—	0.30	—

CPDAI: Composite Psoriatic Disease Activity Index; PASDAS: Psoriatic Arthritis Disease Activity Score; AMDF: arithmetic mean of desirability functions; TJC: tender joint count; SJC: swollen joint count; HAQ: Health Assessment Questionnaire; LEI: Leeds Enthesitis Index; PASI: Psoriasis Area and Severity Index; DLQI: Dermatology Life Quality Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASQoL: Ankylosing Spondylitis Quality of life; PsAQoL: psoriatic arthritis quality of life; SF-36 PCS: Medical Outcome Study Short Form-36 Survey physical component score; VAS: visual analog scale; CRP: C-reactive protein.

Discussion at OMERACT 11

At the start of the module, participants provided clear support for the concept of a new composite disease activity measure for PsA as agreed upon at OMERACT 10 (see voting results, Table 5). Some clinicians raised concern with the concept of a composite score combining very different elements of 1 disease into a single score, and these may not respond similarly to a single therapy. Disease activity in different domains of PsA may be unrelated: for example, arthritis may flare when skin psoriasis is controlled, or vice versa; and there are obviously different treatment implications depending on what element of the disease is active.

However, the potential benefit of such a composite score was also highlighted as being particularly relevant to assessment of disease severity related to “qualifying” for certain treatment options. Some patients may have moderate disease activity, which by involving many different aspects of PsA may severely impair function and QOL. A composite score that accounts for all domains of psoriatic disease may better reflect such a patient’s disease burden. It was agreed that a composite measure was an important research agenda for PsA, but it should be possible to identify the contributions of individual domains to the total disease activity. This could then guide clinicians as to which therapy to choose.

The advantage of all these proposed composite measures is that they provide a numerical measure of disease activity state that can then be used to assess disease activity at 1 timepoint and can be translated into response criteria defined by a minimum change in the score. Potential cutoffs for different levels of disease activity can also be defined and used to guide treatment decisions, acting as targets for treatment or a threshold for biologic therapies.

A specific concern was raised regarding the methodology

of the PASDAS. In the PASDAS, a measure of QOL was included, as well as more specific disease activity measures. This is in contrast to the DAS and ASDAS, similarly developed measures, which do not include QOL domains and have only 1 concept (peripheral joint disease or spinal disease, respectively) assessed within each score, although inclusion of such data have been previously proposed in RCT in SLE. It was questioned whether this methodology could then be used to develop the PASDAS if such different concepts were being combined.

In terms of future planning, it was discussed that the PsA OMERACT group had exercises proposed to engage with patient research partners for further development of these composite measures and also in qualitative research, to ensure that their views of disease activity and assessment are included.

Finally, the feasibility of such a composite score, particularly in routine clinical care, was discussed. There are 2 key feasibility issues with the proposed composite measures. The first is a potential problem for the PASDAS and AMDF related to the complexity of calculating the scores once all the assessments have been done. Both require statistical transformations of all the variables with complex equations. However, all this could be done using a simple spreadsheet or calculator like those used for the RA DAS. The larger feasibility problem affecting all these proposed scoring systems is the necessity to perform a number of different articular and nonarticular outcome assessments to allow calculation of the scores. This has implications on training of rheumatologists and dermatologists to perform these assessments and significant time implications initially if such a scoring system were to be introduced to clinical practice.

Table 5. Voting questions and results from PsA module.

Question	Yes (%)	No (%)	
1 Are existing measures of composite disease activity developed for rheumatoid arthritis appropriate to measure disease activity/response in psoriatic arthritis?	12	88	
2 Do you think a composite measure that only measures inflammatory joint disease and not other musculoskeletal manifestations, nor the skin, is sufficient to measure disease activity in psoriatic arthritis?	7	93	
3 Is it sufficient to assume that the patient and physician will take into account the skin component when determining the global disease assessment?	38	62	
4 Do you think it is feasible to assess all clinical domains in a composite disease activity and responder index for psoriatic disease?	67	33	
5. Measure Truth	Should this measure be considered for further study? (% voting Yes)		
	Discrimination	Feasibility	
PASDAS	47	86	73
AMDF	74	62	70
CPDAI	94	69	88
DAPSA	41	66	19
DAS28	37	73	28

PASDAS: Psoriatic Arthritis Disease Activity Score; AMDF: arithmetic mean of desirability functions; CPDAI: Composite Psoriatic Disease Activity Index; DAPSA: Disease Activity in Psoriatic Arthritis; DAS28: Disease Activity Score 28 joints.

At the end of the module and at the final plenary of the OMERACT meeting, a consensus voting exercise was conducted among all participants to reach agreement on future directions of the PsA OMERACT group. Results are shown in Table 5. The final questions related to the 3 proposed composite indices were presented. There was agreement that further exploration and validation of composite measures was appropriate. However, no measures were ready to be proposed for adoption. Further validation within existing datasets is planned, as well as exercises with patients.

This module provided a valuable opportunity to present and discuss work on potential composite measures in PsA in a forum for discussion. Three measures have been proposed, but further validation and comparison in other datasets, such as those from existing and future interventional studies, are required.

REFERENCES

- Gladman DD, Mease PJ, Krueger G, van der Heijde DM, Antoni C, Helliwell PS, et al. Outcome measures in psoriatic arthritis. *J Rheumatol* 2005;32:2262-9.
- Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. *J Rheumatol* 2007;34:1167-70.
- Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. *Rheumatology* 2005;44:902-6.
- Gladman DD, Landewe R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, et al. Composite measures in psoriatic arthritis: GRAPPA 2008. *J Rheumatol* 2010;37:453-61.
- Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. *Ann Rheum Dis* 2005;64 Suppl 2:ii65-8; discussion ii9-73.
- Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. *Arthritis Rheum* 2004;50:24-35.
- Mease PJ. Assessment tools in psoriatic arthritis. *J Rheumatol* 2008;35:1426-30.
- Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. *Ann Rheum Dis* 2005;64 Suppl 2:ii49-54.
- Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. *J Am Acad Dermatol* 2006;54:685-704.
- van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. *Ann Rheum Dis* 2005;64 Suppl 2:ii61-4.
- Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. *Ann Rheum Dis* 2006;65:1373-8.
- Coates LC, FitzGerald O, Gladman DD, McHugh NJ, Mease P, Strand V, et al. Reduced joint counts misclassify psoriatic arthritis patients with oligoarthritis and miss significant active disease. *Arthritis Rheum* 2013;65:1504-9.
- Clegg DO, Reda DJ, Meijas E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. *Arthritis Rheum* 1996;39:2013-20.
- Gladman DD, Tom BD, Mease PJ, Farewell VT. Informing response criteria for psoriatic arthritis. I: Discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. *J Rheumatol* 2010;37:1892-7.
- Nell-Duxneuner VP, Stamm TA, Machold KP, Pflugbeil S, Aletaha D, Smolen JS. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. *Ann Rheum Dis* 2010;69:546-9.
- Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS. Development of a disease activity index for the assessment of reactive arthritis (DAREA). *Rheumatology* 2000;39:148-55.
- Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. *Dermatologica* 1978;157:238-44.
- Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. *J Am Acad Dermatol* 2004; 51:563-9.
- Berth-Jones J, Thompson J, Papp K. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. *Br J Dermatol* 2008;159:407-12.
- Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. *Br J Rheumatol* 1994;33:834-9.
- Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. *J Rheumatol* 2007;34:123-9.
- Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials: which is the best instrument to use? *J Rheumatol* 2007;34:1302-6.
- Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. *J Rheumatol* 2005;32:1745-50.
- Gladman DD, Inman RD, Cook RJ, van der Heijde D, Landewe RB, Braun J, et al. International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. *J Rheumatol* 2007;34:1733-9.
- Eder L, Chandran V, Shen H, Cook RJ, Gladman DD. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? *Ann Rheum Dis* 2010;69:2160-4.
- Fernandez-Sueiro JL, Willisch A, Pertega-Diaz S, Tasende JA, Fernandez-Lopez JC, Villar NO, et al. Validity of the Bath Ankylosing Spondylitis Disease Activity Index for the evaluation of disease activity in axial psoriatic arthritis. *Arthritis Care Res* 2010;62:78-85.
- Taylor WJ, Harrison AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? *Arthritis Rheum* 2004;51:311-5.
- Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. *Ann Rheum Dis* 2009;68:1387-94.
- Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. *Ann Rheum Dis* 2011;70:272-7.
- Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. *BMJ* 2010;340:c147.
- Fitzgerald O, Helliwell P, Mease P, Mumtaz A, Coates L, Pedersen R, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. *Ann Rheum Dis* 2012;71:358-62.
- Cauli A, Gladman D, Mathieu A, Olivieri I, Ujfalussy I, Scarpa R,

- et al. Patient and physician perception of disease in psoriatic arthritis (PsA). A Multicentre GRAPPA and OMERACT study [abstract]. *Arthritis Rheum* 2007;56 Suppl:S264.
33. Helliwell PS, Fitzgerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). *Ann Rheum Dis* 2013;72:986-91.
34. Fransen J, Kavanaugh A, Borm G. Desirability scores for assessing multiple outcomes in systemic rheumatic diseases. *Commun Stat Theory Methods* 2009;38:3461-71.
35. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. *Ann Rheum Dis* 2010;69:48-53.

Papers presented at the OMERACT 11 Conference,
Pinehurst, NC, USA, May 12–17, 2012

- Part 1 Methods
- Part 2 Imaging and Other Biomarkers
- Part 3 Disease-specific Outcomes I
- Part 4 Disease-specific Outcomes II
- Part 5 The OMERACT Filter 2.0

Part 5 will appear in the May issue.
